“Our team of experts have been working closely with clinicians, lab managers and hospital administrators in Tuscany, and across Italy, to illustrate the value of rapid AST to patients and health systems. This tender is an example of that investment bearing fruit, and we expect to see more tenders across Europe as the body of evidence grows that rapid AST reduces the clinical burden of sepsis and reduces overall costs of managing the disease,” said Stuart Gander, President of Q-linea. 
 
The tender has a validity of three plus two years and a total value of EUR 2,625,900. It involves nine sites across the region of Tuscany for a total of 3,500 tests per year. The tender is issued by ESTAR (Ente di supporto tecnico-amministrativo regionale), the regional administrative technical support body in Tuscany.

About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.